Influence of fever on the pharmacokinetics of ciprofloxacin

International Journal of Antimicrobial Agents

Volumn 11, Issue 1, 1999, Pages 81-85

  Beovič, Bojana ^a   Mrhar, Aleš ^b   Karba, Rihard ^b   Župančič, Tatjana ^b   Iztok Grabnar, ^b   Belič, Aleš ^b   Marolt Gomišček, Marica ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Ciprofloxacin; Fever; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PYELONEPHRITIS; REVIEW;

ADULT; AGED; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; PYELONEPHRITIS;

EID: 0032927053     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00061-2     Document Type: Review

References (10)

1. Sarwari A.R., Mackowiak P.A. The pharmacologic consequences of fever. Infect Dis Clin North Am. 10:1996;21-32.
2. Acharya G., Crevoisier C., Butler T., Ho M., Tiwari M., Stoeckel K., Bradley C.A. Pharmacokinetics of ceftriaxone in patients with typhoid fever. Antimicrob Agents Chemother. 38:1994;2415-2418.
3. Ljungberg B., Nilsson-Ehle I. Advancing age and acute infection influence the kinetics of ceftazidime. Scand J Infect Dis. 21:1989;327-332.
4. Lortholary O., Tod M., Rizzo N., Padoin C., Biard O., Cassasus P., Guillevin L., Petitjean O. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother. 40:1996;1242-1247.
5. Mrhar A., Karba R., Drinovec J., Primožič S., Varl J., Bren A.F., Kozjek F. Computer simulation of ciprofloxacin pharmacokinetics in patients on CAPD. Int J Artif Organs. 13:1990;169-175.
6. Ganzinger U., Halsberger A. Pharmacokinetics of cephalosporins in normal and septicemic rabbits. Antimicrob Agents Chemother. 28:1985;473-477.
7. Nadai M., Hasegawa T., Kato K., Wang L., Nabeshima T., Kato N. Alteration in pharmacokinetics and protein binding behavior of cefazolin in endotoxemic rats. Antimicrob Agents Chemother. 37:1993;1781-1785.
8. Zeng Z.L., Fung K.F. Effects of experimentally induced Streptococcus suis infection on the pharmacokinetics of penicillin G in pigs. J Vet Pharmacol Ther. 13:1990;43-48.
9. Nadai M., Hasegawa T., Kato K., Wang I., Nabeshima T., Kato N. Influence of a bacterial lipopolysaccharide on the pharmacokinetics of tobramycin in rats. J Pharm Pharmacol. 45:1993;971-974.
10. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 28:1995;143-160.